Список литературы

1. Yao J.C., Hassan M., Phan A. et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-72.

2. Kvols L.K. Metastatic carcinoid tumors and the malignant carcinoid syndrome. Ann N Y Acad Sci 1994; 733: 464-70.

3. Eriksson B., Krenning E. et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors - welldifferentiated jejuna-ileal tumor/carcinoma. Neuroendocrinology 2008; 87: 8 - 19.

4. Ruszniewski P., Ish-Shalom S., Wymenga M. et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 2004; 80(4): 244-51.

5. Rinke A., Schade-Brittinger C. et al. PROMID Study Group. Placebocontrolled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27(28): 4656-63. DOI: 10.1200/JCO.2009.22.8510.

6. Caplin M.E., Pavel M., et al. CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014; 371(3): 224-33. DOI: 10.1056/NEJMoa1316158.

7. Pineda E. et al. TTD (Tumores del Tracto Digestivo) Study Group. Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study. BMC Cancer 2013; 13: 427. DOI: 10.1186/1471-2407-13-427.

8. Jann H., Denecke T., Koch M. et al. Impact of octreotide long-acting release on tumour growth control as a first-line treatment in neuroendocrine tumours of pancreatic origin. Neuroendocrinology 2013; 98(2): 137-43. DOI: 10.1159/000353785.

9. Oberg K. Interferon-alpha versus somatostatin or the combination of both in gastroenteropancreatic tumours. Digestion 1996; 57 Suppl 1: 81-3.

10. Raymond E., Dahan L., Raoul J.L. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364(6): 501-13. DOI: 10.1056/NEJMoa1003825.

11. Yao J.C., Shah M.H., Ito T. et al. RAD001 in Advanced neuroendocrine Tumors, 3^rd Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364(6): 514-23. DOI: 10.1056/NEJMoa1009290.

12. Panzuto F., Rinzivillo M., Fazio N. et al. Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist 2014; 19(9): 966-74. DOI: 10.1634/theoncologist.2014-0037.

13. Kamp K., Gumz B., Feelders R.A. et al. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177) Lu-octreotate. Endocr Relat Cancer 2013; 20(6): 825-31. DOI: 10.1530/ERC-13-0254.

14. Hadoux J., Malka D., Planchard D. et al. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. Endocr Relat Cancer 2015; 22(3): 289-98. DOI: 10.1530/ERC-15-0075.

15. Welin S., Sorbye H., Sebjornsen S. et al. Clinical effect of Temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 2011; 117(20): 4617-22. DOI: 10.1002/cncr.26124.

16. Moertel C.G., Kvols L.K., O'Connell M.J., Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68(2): 227-32.

17. Bajetta B., Rimassa L., Carnaghi C. et al. 5-fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 1998; 83: 372-8.

18. Ekeblad S., Sundin A., Janson E.T. et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007; 13: 2986-91.

19. Bajetta E., Catena L., Procopio G. et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 2007; 59: 637-42.

20. Cassier P.A., Walter T., Eymard B. et al. Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single-center experience. Cancer 2009; 115:3392-9.

21. Wells S.A., Asa S.L., Dralle H. et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. The American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Thyroid 2015; 25(6): 567 - 610.

22. Sippel R.S., Kunnimalaiyaan M., Chen H. et al. Current management of medullary thyroid cancer. Oncologist 2008; 13(5): 539-47.

23. Румянцев П.О. Рак щитовидной железы: Современные подходы к диагностике и лечению. М.: ГЭОТАР-Медиа, 2009. 448 с.

24. Roman S., Lin R., Sosa J.A. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006; 107: 2134-42.

25. NCCN Clinical Practice Guidelines in Oncology. Thyroid carcinoma: Version 1.2018. National Comprehensive Cancer Network. Available at https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf.

26. Valerio L., Pieruzzi L., Giani C. et al. Targeted therapy in thyroid cancer: state of the art. Clin Oncol (R Coll Radiol) 2017; 29: 316-24.

27. Wells S.A., Robinson B.G., Gagel R.F. et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012; 30(2): 134-41.

28. Capdevila J, et al, Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumors in clinical practice: a retrospective cross-sectional analysis BMC Cancer 2015; 15: 495 DOI 10.1186/s12885-015-1512-6.

29. Bajetta E et al Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study. Cancer 2014; 120: 2457 - 2463.

30. Yao JC, et al. N Engl J Med 2011; 364: 514 - 523.

31. Albertelli M et al. Safety and Efficacy of High Doses Lanreotide Treatment in Patients with Progressive Neuroendocrine Tumors: Results from a Prospective Phase II Trial Abstract 1929 14th Annual ENETS conference (2017).

32. Martucci VL, Pacak K. Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. Curr Probl Cancer 2014; 38 (1): 7 - 41.

33. Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002; 287: 1427 - 1434.

34. Mullins F, O'Shea P, FitzGerald R, Tormey W. Enzyme-linked immunoassay for plasma-free metanephrines in the biochemical diagnosis of phaeochromocytoma in adults is not ideal. Clin Chem Lab Med. 2012; 50: 105-110.

35. Lenders JWM, Duh Q-Y, Eisenhofer G, Gimenez-Roqueplo A-P, Grebe SKG, Murad MH, Naruse M, Karel Pacak K, Young WFJ. Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2014; 99(6): 1915 - 1942.

36. Janssen I, Blanchet E M, Adams K, Chen C C, Millo C M, Herscovitch P, et al. Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma. Clinical cancer research: an official journal of the American Association for Cancer Research 2015; 17(21): 3888-95.

37. Plouin PF, Amar L, Dekkers OM, Fassnacht M, Gimenez-Roqueplo AP, Lenders JW, Lussey-Lepoutre C, Steichen O; Guideline Working Group. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol. 2016 May; 174(5): G1 - G10.

38. Goers TA, Abdo M, Moley JF, Matthews BD, Quasebarth M, Brunt LM. Outcomes of resection of extra-adrenal pheochromocytomas/paragangliomas in the laparoscopic era: a comparison with adrenal pheochromocytoma. Surg Endosc. 2013; 27: 428 - 433.

39. P Nockel, M El Lakis, A Gaitanidis, L Yang, R Merkel, E Kebebew. - Preoperative genetic testing in pheochromocytomas and paragangliomas influences the surgical approach and the extent of adrenal surgery. - Surgery (2017), doi: 10.1016/j.surg.2017.05.025.

40. Plouin PF, Amar L, Dekkers OM, Fassnacht M, Gimenez-Roqueplo AP, Lenders JW, Lussey-Lepoutre C, Steichen O; Guideline Working Group. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol. 2016 May; 174(5): G1 - G10.

41. Baudin et al. European Journal of Endocrinology (2014) - Therapy for malignant chromaffin tumors.

42. Neuroendocrinology. ENETS 2017 Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors. Vol. 105, N 3, 2017Б p. 192 - 330.

43. Neuroendocrinology 2015; 101: 1 - 17 The Status of Neuroendocrine Tumor Imaging: From Darkness to Light? Lisa Bodei, Anders Sundin, Mark Kidd, Vikas Prasad, Irvin M. Modlin.

44. Visc Med 2017; 33: 358 - 366 Theranostics of Neuroendocrine Tumors Sze Ting Lee, Harshad R. Kulkarni, Aviral Singh, Richard P. Baum.

45. Hicks, R.J., et al. Eur J Nucl Med Mol Imaging (2019) 46: 2112.

46. Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma The American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma Thyroid. 2015 Jun 1; 25(6): 567 - 610.

47. Cancers (Basel). 2018 Dec; 10(12): 510. Management of Typical and Atypical Pulmonary Carcinoids Based on Different Established Guidelines Rohit Gosain, Sarbajit Mukherjee, Sai S. Yendamuri, and Renuka Iyer.

48. Shah M.H. et al. NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2.2018//Journal of the National Comprehensive Cancer Network. - 2018. - Т. 16. - N. 6. - С. 693 - 702.

49. Bichakjian C.K. et al. Merkel cell carcinoma, version 1.2018, NCCN clinical practice guidelines in oncology//Journal of the National Comprehensive Cancer Network. - 2018. - Т. 16. - N. 6. - С. 742 - 774.

50. Bushnell DL, Baum RP. Standard imaging techniques for neuroendocrine tumors. Endocrinol. Metab. Clin. N. Am. 2011; 40: 153 - 162.

51. Yamaguchi T, et al: Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci 2014; 105: 1176 - 1181.

52. Sorbye H, et al: Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 2013; 24: 152 - 160.

53. Neuroendocrinology ENETS 2016 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: An Update 2016; 103: 186 - 194.

54. NCCN Clinical Practice Guidelines in Oncology. Neuroendocrine tumors: Version 2.2017. National Comprehensive Cancer Network.

55. et al. Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up//Annals of oncology. - 2012. - Т. 23. - N. suppl_7. - С. vii120 - vii123.

56. et al. Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up//Annals of Oncology. - 2010. - Т. 21. - N. suppl_5. - С. v223 - v227.

57. Knigge U. et al. ENETS consensus recommendations for the standards of care in neuroendocrine neoplasms: follow-up and documentation//Neuroendocrinology. - 2017. - Т. 105. - N. 3. - С. 310 - 319.

58. Cifu D.X., Lew H.L. Braddom s Rehabilitation Care: A Clinical Handbook E-Book. - Elsevier Health Sciences, 2017.

59. Van den Berg J.P. et al. Guideline "Cancer rehabilitation"//Nederlands tijdschrift voor geneeskunde. - 2011. - Т. 155. - N. 51. - С. A4104.

60. Fu J.B., Morishita S. The future of rehabilitation in oncology. - 2017.

61. Blesch K.S. Rehabilitation of the cancer patient at home//Seminars in oncology nursing. - WB Saunders, 1996. - Т. 12. - N. 3. - С. 219 - 225.

62. Sundin A. et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine and hybrid imaging//Neuroendocrinology. - 2017. - Т. 105. - N. 3. - С. 212 - 244.

63. Muth A. et al. Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma//Journal of internal medicine. - 2019. - Т. 285. - N. 2. - С. 187 - 204.

64. et al. Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review. - 2017.

65. Баранова О.Д. и др. Радионуклидная визуализация и терапия у пациентов с нейроэндокринными опухолями//Эндокринная хирургия. - 2017. - Т. 11. - N. 4.

66. Bombardieri E. et al. 111 In-pentetreotide scintigraphy: procedure guidelines for tumour imaging//European journal of nuclear medicine and molecular imaging. - 2010. - Т. 37. - N. 7. - С. 1441 - 1448.

67. Kjaer A., Knigge U. Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors//Scandinavian journal of gastroenterology. - 2015. - Т. 50. - N. 6. - С. 740 - 747.

68. Arora, G., & Bandopadhyaya, G. (2018). Paradigm shift in theranostics of neuroendocrine tumors: conceptual horizons of nanotechnology in nuclear medicine. Annals of Nuclear Medicine, 32(3), 151 - 164. doi: 10.1007/s12149-018-1235-2.

69. Raphael M.J. et al. Principles of diagnosis and management of neuroendocrine tumours//CMAJ. - 2017. - Т. 189. - N. 10. - С. E398 - E404.

70. Rinke A. et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival//Neuroendocrinology. - 2017. - Т. 104. - N. 1. - С. 26 - 32.

71. Rinke A. et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group//J Clin Oncol. - 2009. - Т. 27. - N. 28. - С. 4656 - 4663.

72. Caplin M.E. et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors//New England Journal of Medicine. - 2014. - Т. 371. - N. 3. - С. 224 - 233.

73. Lee A. et al. Systematic review of the role of targeted therapy in metastatic neuroendocrine tumors//Neuroendocrinology. - 2017. - Т. 104. - N. 3. - С. 209 - 222.

74. Persson, G., Franzn, S., & Ahrn, B. (2003). Randomized clinical trial of the effect of interferon on survival in patients with disseminated midgut carcinoid tumours. British Journal of Surgery, 90(6), 687 - 693. doi: 10.1002/bjs.4149.

75. Fazio, N., de Braud, F., Delle Fave, G., & Oberg, K. (2006). Interferon- and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination? Annals of Oncology, 18(1), 13 - 19. doi: 10.1093/annonc/mdl144.

76. Bajetta, E., Catena, L., Procopio, G., De Dosso, S., Bichisao, E., Ferrari, L., ... Bajetta, R. (2006). Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemotherapy and Pharmacology, 59(5), 637-642. doi: 10.1007/s00280-006-0306-6.

77. Bongiovanni A. et al. Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature//OncoTargets and therapy. - 2014. - Т. 7. - С. 1919.

78. Tafuto S. et al. Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms//Journal of clinical medicine. - 2019. - Т. 8. - N. 8. - С. 1224.

79. Spada, F., Antonuzzo, L., Marconcini, R., Radice, D., Antonuzzo, A., Ricci, S., ... Fazio, N. (2016). Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors. Neuroendocrinology, 103(6), 806 - 814. doi: 10.1159/000444087.

80. Brixi-Benmansour, H., Jouve, J.-L., Mitry, E., Bonnetain, F., Landi, B., Hentic, O., ... Cadiot, G. (2011). Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma. Digestive and Liver Disease, 43(11), 912 - 916. doi: 10.1016/j.dld.2011.07.001.

81. Spada, F., Antonuzzo, L., Marconcini, R., Radice, D., Antonuzzo, A., Ricci, S., ... Fazio, N. (2016). Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors. Neuroendocrinology, 103(6), 806 - 814. doi:10.1159/000444087.

82. Garcia-Carbonero R. et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas//Neuroendocrinology. - 2016. - Т. 103. - N. 2. - С. 186 - 194.

83. Stueven A.K. et al. Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future//International journal of molecular sciences. - 2019. - Т. 20. - N. 12. - С. 3049.

84. RUSSCO. Практические рекомендации по лекарственному лечению нейроэндокринных опухолей желудочнокишечного тракта, поджелудочной железы и других локализаций. URL: https://rosoncoweb.ru/standarts/RUSSCO/2019/2019-29.pdf.

85. RUSSCO. Практические рекомендации по лекарственному лечению нейроэндокринных опухолей легких и тимуса. URL: https://rosoncoweb.ru/standarts/RUSSCO/2019/2019-04.pdf.

86. Iwasa S. et al. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas//Japanese journal of clinical oncology. - 2010. - Т. 40. - N. 4. - С. 313 - 318.

87. Mirvis E. et al. Role of interferon-alpha in patients with neuroendocrine tumors: a retrospective study//Anticancer research. - 2014. - Т. 34. - N. 11. - С. 6601 - 6607.

88. Hadoux J. et al. Interferon-alpha treatment for disease control in metastatic pheochromocytoma/paraganglioma patients//Hormones and Cancer. - 2017. - Т. 8. - N. 5 - 6. - С. 330 - 337.

89. Niemeijer N.D. et al. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta analysis//Clinical endocrinology. - 2014. - Т. 81. - N. 5. - С. 642 - 651.

90. Hescot S. et al. One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma//The Journal of Clinical Endocrinology & Metabolism. - 2013. - Т. 98. - N. 10. - С. 4006 - 4012.

91. Nagaraja V., Eslick G. D., Edirimanne S. Recurrence and functional outcomes of partial adrenalectomy: a systematic review and meta-analysis//International Journal of Surgery. - 2015. - Т. 16. - С. 7 - 13.

92. Amar L. et al. MANAGEMENT OF ENDOCRINE DISEASE: Recurrence or new tumors after complete resection of pheochromocytomas and paragangliomas: a systematic review and meta-analysis//European journal of endocrinology. - 2016. - Т. 175. - N. 4. - С. R135 - R145.

93. Van der Horst-Schrivers A.N., Kerstens M.N., Wolffenbuttel B.H. Preoperative pharmacological management of phaeochromocytoma//Neth J Med. - 2006. - Т. 64. - N. 8. - С. 290 - 5.

94. Панькив В.И. Феохромоцитома: этиология, патогенез, диагностика, клинические особенности, лечение//Международный эндокринологический журнал. - 2011. - N. 8(40).

95. Jimenez, P., Tatsui, C., Jessop, A., Thosani, S., & Jimenez, C. (2017). Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress. Current Oncology Reports, 19(12). doi: 10.1007/s11912-017-0643-0.

96. Sharp SE, Trout AT, Weiss BD, Gelfand MJ. MIBG in Neuroblastoma Diagnostic Imaging and Therapy.

97. Neuroendocrinology 2015; 101: 1 - 17 The Status of Neuroendocrine Tumor Imaging: From Darkness to Light? Lisa Bodei, Anders Sundin, Mark Kidd, Vikas Prasad, Irvin M. Modlin DOI: 10.1159/000367850.

98. Fluorine-18-fluorodihydroxyphenylalanine Positron-emission Tomography Scans of Neuroendocrine Tumors (Carcinoids and Pheochromocytomas). Zanzi I, Studentsova Y, Bjelke D, Warner R, Babchyck B, Chaly T DOI: 10.4103/jcis.JCIS_107_16.

99. Irene Virgolini et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE (Eur J Nucl Med Mol Imaging (2010) 37: 2004 - 2010 DOI 10.1007/s00259-010-1512-3).

100. Neuroendokrine Tumoren Klassifikation, Klinik und Bildgebung Neuroendocrine tumors Classification, clinical presentation and imaging H. F. Raue & K. Frank-Raue DOI: 10.1007/s00117-019-0574-x.

101. 99mTc-EDDA/HYNIC-TOC is a New Opportunity in Neuroendocrine Tumors of the Lung (and in other Malignant and Benign Pulmonary Diseases) Vittorio Briganti, Vincenzo Cuccurullo*, Valentina Berti, Giuseppe Danilo Di Stasio, Flavia Linguanti, Francesco Mungai, Luigi Mansi. DOI: 10.2174/1874471013666191230143610.

102. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging Emilio Bombardieri & Valentina Ambrosini & Cumali Aktolun & Richard P. Baum & Angelica Bishof-Delaloye & Silvana Del Vecchio & Lorenzo Maffioli & Luc Mortelmans & Wim Oyen & Giovanna Pepe & Arturo Chiti.

103. Neuroendokrine Tumoren Klassifikation, Klinik und Bildgebung Neuroendocrine tumors Classification, clinical presentation and imaging H. F. Raue & K. Frank-Raue DOI: 10.1007/s00117-019-0574-x.

104. Irene Virgolini et al. Procedure guidelines for PET/CT tumour imaging with ⁶⁸Ga-DOTA-conjugated peptides: ⁶⁸Ga-DOTA-TOC, ⁶⁸Ga-DOTA-NOC, ⁶⁸Ga-DOTA-TATE (Eur J Nucl Med Mol Imaging (2010) 37: 2004 - 2010 DOI 10.1007/s00259-010-1512-3).